Lakefront Biotherapeutics American Depositary Shares
LKFT
64 hedge funds and large institutions have $868M invested in Lakefront Biotherapeutics American Depositary Shares in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
111% more call options, than puts
Call options by funds: $19K | Put options by funds: $9K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
35% more capital invested
Capital invested by funds: $642M → $868M (+$226M)
23% more funds holding
Funds holding: 52 → 64 (+12)
0.13% more ownership
Funds ownership: 15.23% → 15.36% (+0.13%)
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.8M |
| 2 |
Renaissance Technologies
New York
|
+$7.61M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$4.16M |
| 4 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$3.93M |
| 5 |
GAMA
Graticule Asia Macro Advisors
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$11.8M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.56M |
| 3 |
Goldman Sachs
New York
|
-$3.1M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.45M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.39M |
LKFT Hedge Fund Activity: Q1 2017 in Review
64 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2017, worth a combined $868M — up 35% from $642M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LKFT positions and 9 closed out — a net gain of 12 holders — while 14 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $10.8M. The largest seller was Deerfield Management, cutting an estimated $11.8M.
- 64 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2017, up from 52 in Q4 2016.
- Funds reported $868M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2017, up 35% quarter-over-quarter.
- 21 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2017 and 9 closed out, a net change of +12 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2017 was BlackRock, an estimated $10.8M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2017 was Deerfield Management, an estimated $11.8M sold.
Based on aggregated 13F filings for Q1 2017.